Heparin-releasing scaffold for stem cells: a differentiating device for vascular aims

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Shin’oka T, Shum-Tim D, Ma PX et al.: Creation of viable pulmonary artery autografts through tissue engineering. J. Thorac. Cardiovasc. Surg.115(3),536–545; discussion 545–536 (1998).
  MedlineGoogle Scholar
• 2  Shin’oka T, Matsumura G, Hibino N et al.: Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J. Thorac. Cardiovasc. Surg.129(6),1330–1338 (2005).
  MedlineGoogle Scholar
• 3  Sarkar S, Lee GY, Wong JY, Desai TA: Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials27(27),4775–4782 (2006).
  Medline CASGoogle Scholar
• 4  Greisler HP, Cziperle DJ, Kim DU et al.: Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment. Surgery112(2),244–254; discussion 254–245 (1992).
  Medline CASGoogle Scholar
• 5  Spadaccio C, Chello M, Trombetta M, Rainer A, Toyoda Y, Genovese J: Drug releasing systems in cardiovascular tissue engineering. J. Cell. Mol. Med.13(3),422–439 (2009).▪ Provides an extensive overview on tissue engineering for cardiovascular structures, with particular attention to scaffold fabrication techniques, functionalization with bioactive molecules, drug delivery systems and their applications in this field.
  Medline CASGoogle Scholar
• 6  Xu C, Inai R, Kotaki M, Ramakrishna S: Electrospun nanofiber fabrication as synthetic extracellular matrix and its potential for vascular tissue engineering. Tissue Eng.10(7–8),1160–1168 (2004).▪ Provides an extensive description of the characteristics and advantages of nanofabrication by means of the electrospinning technique, underlining the importance of mimicking extracellular matrix structural properties in vascular tissue engineering.
  Medline CASGoogle Scholar
• 7  Badami AS, Kreke MR, Thompson MS, Riffle JS, Goldstein AS: Effect of fiber diameter on spreading, proliferation, and differentiation of osteoblastic cells on electrospun poly(lactic acid) substrates. Biomaterials27(4),596–606 (2006).
  Medline CASGoogle Scholar
• 8  Hashi CK, Zhu Y, Yang GY et al.: Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc. Natl Acad. Sci. USA104(29),11915–11920 (2007).▪ Experimental work confirms the advantage of mimicking the arrangement of connective tissue fibrillar proteins using nano- and microfibrous electrospun scaffolds. Also underlines the role of mesenchymal stem cells as a potential alternative to autologous endothelial cells in a tissue-engineered vascular graft, for their easy availability and recruitment, high plasticity and antithrombogenic properties probably related to the presence of heparin-like proteoglicans expressed on their membrane.
  Medline CASGoogle Scholar
• 9  Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM: Controlled release of heparin from poly(e-caprolactone) electrospun fibers. Biomaterials27(9),2042–2050 (2006).▪ Represents an example of successful polymer functionalization performed on electrospun poly-caprolactone nanofibers, providing important data on heparin-release assays and interesting references on electrospun fibers drug loading.
  Medline CASGoogle Scholar
• 10  Huang ZM, Zhang ZY, Kotaki M, Ramakrishna S: A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Compos. Sci. Technol.63,2223–2253 (2003).
  CASGoogle Scholar
• 11  Salacinski HJ, Tiwari A, Hamilton G, Seifalian AM: Cellular engineering of vascular bypass grafts: role of chemical coatings for enhancing endothelial cell attachment. Med. Biol. Eng. Comput.39(6),609–618 (2001).▪ Describes current limitations of tissue-engineered vascular grafts mainly concerning cell type, availability, differentiation and growth inside the construct, thrombogenicity, mechanical resistance, and reasonable and clinically suitable timing for scaffold preparation.
  Medline CASGoogle Scholar
• 12  Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis9(1),1–20 (1989).
  Medline CASGoogle Scholar
• 13  Zilla P, Deutsch M, Meinhart J et al.: Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J. Vasc. Surg.19(3),540–548 (1994).
  Medline CASGoogle Scholar
• 14  Rosenman JE, Kempczinski RF, Pearce WH, Silberstein EB: Kinetics of endothelial cell seeding. J. Vasc. Surg.2(6),778–784 (1985).
  Medline CASGoogle Scholar
• 15  Spadaccio C, Rainer A, Chello M, Covino E, Trombetta M, Genovese J: Drug releasing hybrid scaffold: new avenue in cardiovascular tissue engineering. Tissue Eng. Part A14(5),691–943 (2008).▪ Contains preliminary data on the use of heparin functionalized electrospun scaffolds to produce tailored extracellular matrix (ECM)-like differentiating devices using human mesenchymal stem cells for cardiovascular applications.
  Google Scholar
• 16  Spadaccio C, Rainer A, Trombetta M et al.: Poly-L-lactic acid/hydroxyapatite electrospun nanocomposites induce chondrogenic differentiation of human MSC. Ann. Biomed. Eng.37(7),1376–1389 (2009).▪ Represents a proof of principle of the possibility to produce a scaffold suitable for stem cell seeding, containing the appropriate factors to induce a guided differentiation towards the desired phenotype within a 3D ECM-like environment closely mimicking the native tissue histoarchitecture, and allowing a harmonious ongoing growth and differentiation for tissue regeneration.
  MedlineGoogle Scholar
• 17  Lobo BL, Greene WL: ACCP consensus conference on antithrombotic therapy. Indicate specific low molecular weight heparin product and dosage. Chest110(3),866 (1996).
  Medline CASGoogle Scholar
• 18  Rawat A, Yang T, Hussain A, Ahsan F: Complexation of a poly-L-arginine with low molecular weight heparin enhances pulmonary absorption of the drug. Pharm. Res.25(4),936–948 (2008).
  Medline CASGoogle Scholar
• 19  Sell SA, McClure MJ, Barnes CP et al.: Electrospun polydioxanone-elastin blends: potential for bioresorbable vascular grafts. Biomed. Mater.1(2),72–80 (2006).
  Medline CASGoogle Scholar
• 20  Smith MJ, Mcclure MJ, Sell SA et al.: Suture-reinforced electrospun polydioxanone-elastin small-diameter tubes for use in vascular tissue engineering: a feasibility study. Acta Biomater.4(1),58–66 (2008).
  Medline CASGoogle Scholar
• 21  Stankus JJ, Soletti L, Fujimoto K, Hong Y, Vorp DA, Wagner WR: Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials28(17),2738–2746 (2007).
  Medline CASGoogle Scholar
• 22  Nieponice A, Soletti L, Guan J et al.: Development of a tissue-engineered vascular graft combining a biodegradable scaffold, muscle-derived stem cells and a rotational vacuum seeding technique. Biomaterials29(7),825–833 (2008).
  Medline CASGoogle Scholar
• 23  Konig G, Mcallister TN, Dusserre N et al.: Mechanical properties of completely autologous human tissue engineered blood vessels compared with human saphenous vein and mammary artery. Biomaterials30(8),1542–1550 (2009).
  Medline CASGoogle Scholar
• 24  Kim BS, Putnam AJ, Kulik TJ, Mooney DJ: Optimizing seeding and culture methods to engineer smooth muscle tissue on biodegradable polymer matrices. Biotechnol. Bioeng.57(1),46–54 (1998).
  Medline CASGoogle Scholar
• 25  Soletti L, Hong Y, Guan J et al.: A bilayered elastomeric scaffold for tissue engineering of small diameter vascular grafts. Acta Biomater.6(1),110–122 (2010).
  Medline CASGoogle Scholar
• 26  George J, Onodera J, Miyata T: Biodegradable honeycomb collagen scaffold for dermal tissue engineering. J. Biomed. Mater. Res. A87(4),1103–1111 (2008).
  MedlineGoogle Scholar
• 27  Genovese JA, Spadaccio C, Langer J, Habe J, Jackson J, Patel AN: Electrostimulation induces cardiomyocyte predifferentiation of fibroblasts. Biochem. Biophys. Res. Commun.370(3),450–455 (2008).
  Medline CASGoogle Scholar
• 28  Onodera N, Tamaki T, Okada Y, Akatsuka A, Aoki D: Identification of tissue-specific vasculogenic cells originating from murine uterus. Histochem. Cell Biol.125(6),625–635 (2006).
  Medline CASGoogle Scholar
• 29  Jaques LB, Sue TK, Mcduffie NM, Wice SM: Heparin and sulfated mucopolysaccharides – a micro system for quantitative differentiation and determination. Can. J. Physiol. Pharmacol.55(5),1179–1189 (1977).
  Medline CASGoogle Scholar
• 30  Yang Z, Birkenhauer P, Julmy F et al.: Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J. Control Release60(2–3),269–277 (1999).
  Medline CASGoogle Scholar
• 31  Kent KC, Oshima A, Whittemore AD: Optimal seeding conditions for human endothelial cells. Ann. Vasc. Surg.6(3),258–264 (1992).
  Medline CASGoogle Scholar
• 32  Pham QP, Sharma U, Mikos AG: Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng.12(5),1197–1211 (2006).▪ Examines the crucial role of heparin in endothelial cell adhesion and homeostasis, and provides clues regarding its capability to improve cell attachment to the scaffold, providing trophic and differentiating signaling and acting as a depot role in the ECM for the growth factors, improving their release and enhancing their stability against thermal denaturation and enzymatic digestion.
  Medline CASGoogle Scholar
• 33  Yoon JJ, Chung HJ, Lee HJ, Park TG: Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J. Biomed. Mater. Res. A79(4),934–942 (2006).
  MedlineGoogle Scholar
• 34  Cai S, Liu Y, Zheng Shu X, Prestwich GD: Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials26(30),6054–6067 (2005).
  Medline CASGoogle Scholar
• 35  Chung HJ, Kim HK, Yoon JJ, Park TG: Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm. Res.23(8),1835–1841 (2006).
  Medline CASGoogle Scholar
• 36  Casper CL, Yamaguchi N, Kiick KL, Rabolt JF: Functionalizing electrospun fibers with biologically relevant macromolecules. Biomacromolecules6(4),1998–2007 (2005).
  Medline CASGoogle Scholar
• 37  Serizawa N, Takei Y, Okubo H, Yamasina S, Enomoto N, Sato N: Effect of low-molecular-weight heparin on the commitment of bone marrow cells to liver sinusoidal endothelial cells in CCL(4)-induced liver injury. Hepatol. Res.34(4),207–213 (2006).
  Medline CASGoogle Scholar
• 38  Centola M, Rainer A, Spadaccio C, De Porcellinis S, Genovese J, Trombetta M: Combining electrospinning and fused deposition modeling for the fabrication of a hybrid vascular graft. Biofabrication (2010) (In Press).
  MedlineGoogle Scholar
• 39  Sank A, Wei D, Reid J et al.: Human endothelial cells are defective in diabetic vascular disease. J. Surg. Res.57(6),647–653 (1994).▪ Describes different functionalization techniques for tissue engineering, underlining the advantage of direct incorporation of biomolecules in the polymer solution in order to overcome the drawbacks of other methods, such as adsorption or microencapsulation.
  Medline CASGoogle Scholar
• 40  Guan J, Stankus JJ, Wagner WR: Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J. Control Release120(1–2),70–78 (2007).
  Medline CASGoogle Scholar
• 41  Chabut D, Fischer AM, Colliec-Jouault S et al.: Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent a6 overexpression. Mol. Pharmacol.64(3),696–702 (2003).▪ Contains relevant data concerning the heparin dosage capable of inducing endothelial differentiation in culture conditions.
  Medline CASGoogle Scholar
• 42  Bezuidenhout D, Davies N, Black M, Schmidt C, Oosthuysen A, Zilla P: Covalent surface heparinization potentiates porous polyurethane scaffold vascularization. J. Biomater. Appl.24(5),401–418 (2008).▪ Reports the effect of heparin in the inhibition of smooth muscle proliferation and intimal hyperplasia, allowing speculation on the possible advantages of the proposed heparin functionalized poly-L-lactide scaffold in the control of the phenomena recognized to be at the root of graft restenosis.
  MedlineGoogle Scholar
• 43  Glagov S: Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation89(6),2888–2891 (1994).
  Medline CASGoogle Scholar
• 44  Edelman ER, Nathan A, Katada M, Gates J, Karnovsky MJ: Perivascular graft heparin delivery using biodegradable polymer wraps. Biomaterials21(22),2279–2286 (2000).
  Medline CASGoogle Scholar